Abstract:<div class="abstract-group"> <section class="article-section article-section__abstract" lang="en" data-lang="en" id="section-1-en"> <h3 class="article-section__header main abstractlang_en main">Abstract</h3> <div class="article-section__content en main"> <p>Calcium‐activated chloride channels (CaCCs) are ion channels with key roles in physiological processes. They are abnormally expressed in various cancers, including esophageal squamous cell cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastrointestinal stromal tumors. The CaCC component TMEM16A/ANO1 was recently shown to be overexpressed in lung adenocarcinoma cells and may serve as a tumorigenic protein. In this study, we determined that matrine is a potent TMEM16A inhibitor that exerts anti‐lung adenocarcinoma effects. Patch clamp experiments showed that matrine inhibited TMEM16A current in a concentration‐dependent manner with an IC<sub>50</sub> of 27.94 ± 4.78 μM. Molecular simulation and site‐directed mutation experiments demonstrated that the matrine‐sensitive sites of the TMEM16A channel involve the amino acids Y355, F411, and F415. Results of cell viability and wound healing assays showed that matrine significantly inhibited the proliferation and migration of LA795 cells, which exhibit high TMEM16A expression. In contrast, matrine has only weak inhibitory effect on CCD‐19Lu and HeLa cells lacking TMEM16A expression. Matrine‐induced effects on the proliferation and migration of LA795 cells were abrogated upon shRNA‐mediated TMEM16A knockdown in LA795 cells. Finally, in vivo experiments demonstrated that matrine dramatically inhibited the growth of lung adenocarcinoma xenograft tumors in mice but did not affect mouse body weight. Collectively, these data indicate that matrine is an effective and safe TMEM16A inhibitor and that TMEM16A is the target of matrine anti‐lung adenocarcinoma activity. These findings provide new insight for the development of novel treatments for lung adenocarcinoma. </p>

Dedifferentiated Acinic Cell (Acinous) Carcinoma of the Parotid Gland

Downregulation of ANO1 activity in PC‐9 cells modulated by a new novel candidate TMEMinh001

Inhibition of Calcium-Activated Chloride Channel ANO1/TMEM16A Suppresses Tumor Growth and Invasion in Human Lung Cancer

Advances in Anoctamin 1: A Potential New Drug Target in Medicinal Chemistry

The Ca<SUP>2+</SUP>-activated chloride channel ANO1/TMEM16A: An emerging therapeutic target for epithelium-originated diseases?

Inhibition of Ca2+-activated Cl− Channel ANO1/TMEM16A Expression Suppresses Tumor Growth and Invasiveness in Human Prostate Carcinoma

Diethylstilbestrol, a Novel ANO1 Inhibitor, Exerts an Anticancer Effect on Non-Small Cell Lung Cancer via Inhibition of ANO1

A novel microscopy-based assay identifies extended synaptotagmin-1 (ESYT1) as a positive regulator of anoctamin 1 traffic

A review of ANO1-based calcium activated chloride channel modulators

Inhibition of Calcium-Activated Chloride Channel ANO1 Suppresses Proliferation and Induces Apoptosis of Epithelium Originated Cancer Cells

Design of Anticancer 2,4-Diaminopyrimidines as Novel Anoctamin 1 (ANO1) Ion Channel Blockers

ANO1 reprograms cholesterol metabolism and the tumor microenvironment to promote cancer metastasis

Benzophenanthridine alkaloids suppress lung adenocarcinoma by blocking TMEM16A Ca2+-activated Cl- channels

Distinguishing androgenetic alopecia from chronic telogen effluvium when associated in the same patient: a simple noninvasive method.

Discovery of a novel natural compound, vitekwangin B, with ANO1 protein reduction properties and anticancer potential

Discovery of 4-Arylthiophene-3-carboxylic Acid As Inhibitor of ANO1 and Its Effect As Analgesic Agent

ANO1 Protein As a Potential Biomarker for Esophageal Cancer Prognosis and Precancerous Lesion Development Prediction.

Matrine is a novel inhibitor of the TMEM16A chloride channel with antilung adenocarcinoma effects

Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1

Identification of a Novel Autophagic Inhibitor Cepharanthine to Enhance the Anti-Cancer Property of Dacomitinib in Non-Small Cell Lung Cancer.

Pharmacological Activity of Cepharanthine